DoubleChecks

What was claimed

Pretty soon, if you need access to an experimental new drug—for your rare type of cancer—you'll be going to Montana. The state is going to allow Americans to access drugs that passed a phase I trial, making miracle cures accessible long before FDA approval

Our verdict

Needs caution

Montana has passed laws (SB 422 and SB 535) that broadly expand access to experimental treatments that completed Phase I trials, and commentators do describe it as a hub or "playground" for experimental medicine. However, there is no evidence that people with rare cancers in general "will" be going to Montana, and travel patterns or future behavior of patients cannot be reliably predicted from current sources. Phase I completion indicates limited safety data but not proven efficacy; many Phase I agents never reach approval and manufacturers decide whether to supply products, so widespread access to safe, effective “miracle cures” is unlikely and speculative.

All 3 AI systems agree15 sources citedChecked Jul 31, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

Pretty soon, if you need access to an experimental new drug for your rare type of cancer, you'll be going to Montana

Misleading84%
All 2 AIs agree

This change will make miracle cures accessible long before FDA approval.

Misleading89%
All 2 AIs agree

The state is going to allow Americans to access drugs that passed a phase I trial, making miracle cures accessible long before FDA approval.

Verified94%
3 of 4 AIs agree·Perplexity: Misleading

Verified against 15 sources

vice.comtheconversation.comduanemorris.comgizmodo.comberkleyls.comgmdpacademy.orgiflscience.comberkleyls.comlinkedin.comyoutube.comlinkedin.comfightaging.orglinkedin.comwsj.compolicylab.us

Detailed Analysis

The core description of Montana’s law allowing access to drugs that have only passed Phase I trials is accurate and well supported. However, the response is partly speculative and uses misleading rhetoric like “miracle cures” and implying people with rare cancers will routinely go to Montana for treatment. These future-oriented and value-laden claims cannot be verified and overstate what the law guarantees.

Why this verdict

  • The core description of Montana’s law allowing access to drugs that have only passed Phase I trials is accurate and well supported.
  • However, the response is partly speculative and uses misleading rhetoric like “miracle cures” and implying people with rare cancers will routinely go to Montana for treatment.
  • These future-oriented and value-laden claims cannot be verified and overstate what the law guarantees.

Claims checked

Pretty soon, if you need access to an experimental new drug—for your rare type of cancer—you'll be going to Montana.

Misleading83%
Montana has passed laws (SB 422 and SB 535) that broadly expand access to experimental treatments that completed Phase I trials, and commentators do describe it as a hub or "playground" for experimental medicine.[1] [3] [5] [9] [12] [14] However, there is no evidence that people with rare cancers in general "will" be going to Montana, and travel patterns or future behavior of patients cannot be reliably predicted from current sources.[2] [6] [14]

This claim may mislead readers without added context.

The state is going to allow Americans to access drugs that passed a phase I trial, making miracle cures accessible long before FDA approval.

Misleading90%
Phase I trials primarily assess safety and dosage in small groups and do not establish that a drug is effective or a "miracle cure."[2] [3] [5] [6] [12] While Montana’s law does allow access long before full FDA approval, calling these drugs "miracle cures" overstates their proven benefit and contradicts sources that emphasize most Phase I drugs never become approved treatments.[2] [5] [12]

This claim may mislead readers without added context.

The state is going to allow Americans to access drugs that passed a phase I trial.

Verified95%
Montana’s SB 422 (2023) and SB 535 (2025) explicitly allow patients to access experimental treatments that have successfully completed Phase I clinical trials but lack full FDA approval.[3] [5] [8] [11] [12] These laws apply broadly to patients (not only in-state residents) who meet the informed consent and clinical requirements.[3] [5] [8]

What other AI think

The statement is largely factually accurate about Montana's law allowing Phase I drugs, but contains a significant misleading claim about "miracle cures." Phase I trials test only safety, not efficacy, and most Phase I drugs never gain approval. The framing suggests these are proven treatments, which contradicts the evidence.

Why this verdict

  • The statement is largely factually accurate about Montana's law allowing Phase I drugs, but contains a significant misleading claim about "miracle cures." Phase I trials test only safety, not efficacy, and most Phase I drugs never gain approval.
  • The framing suggests these are proven treatments, which contradicts the evidence.

Claims checked

Pretty soon, if you need access to an experimental new drug for your rare type of cancer, you'll be going to Montana

Misleading85%
While technically true that Montana allows this access, the statement implies this is a unique advantage. However, the law only applies to drugs manufactured in Montana due to federal interstate commerce restrictions, significantly limiting its practical scope.

This claim may mislead readers without added context.

Making miracle cures accessible long before FDA approval

Misleading90%
Phase I trials test only safety, not efficacy. Only about 12% of Phase I drugs gain full FDA approval. Calling them 'miracle cures' is misleading—they are unproven treatments with unknown effectiveness and potential severe side effects.

This claim may mislead readers without added context.

Montana will allow Americans to access drugs that passed a phase I trial

Verified95%
Senate Bill 535, signed in May 2025, explicitly allows access to drugs that have completed Phase I clinical trials through licensed experimental treatment centers.
The core legal claim about Montana changing its laws is accurate: the state passed SB 535 to create licensed Experimental Treatment Centers and broaden Right-to-Try access to investigational products that have completed Phase I. However, the statement that this will make “miracle cures” broadly accessible long before FDA approval is speculative and misleading because Phase I completion only addresses early safety, not proven effectiveness, and manufacturers often control availability.

Why this verdict

  • The core legal claim about Montana changing its laws is accurate: the state passed SB 535 to create licensed Experimental Treatment Centers and broaden Right-to-Try access to investigational products that have completed Phase I.
  • However, the statement that this will make “miracle cures” broadly accessible long before FDA approval is speculative and misleading because Phase I completion only addresses early safety, not proven effectiveness, and manufacturers often control availability.

Claims checked

This change will make miracle cures accessible long before FDA approval.

Misleading88%
Phase I completion indicates limited safety data but not proven efficacy; many Phase I agents never reach approval and manufacturers decide whether to supply products, so widespread access to safe, effective “miracle cures” is unlikely and speculative.

This claim may mislead readers without added context.

Montana is going to allow Americans to access drugs that passed a Phase I trial (via new law).

Verified92%
Montana enacted legislation (SB 535, signed in 2025) establishing licensed Experimental Treatment Centers and updating Right‑to‑Try rules to permit provision of investigational drugs that have completed Phase I safety trials.

Share this result

Try DoubleChecks